Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Lexicon Pharmaceuticals Inc’s stock clocked out at $0.68, down -6.06% from its previous closing price of $0.72. In other words, the price has decreased by -$6.06 from its previous closing price. On the day, 3.49 million shares were traded. LXRX stock price reached its highest trading level at $0.743 during the session, while it also had its lowest trading level at $0.6806.
Ratios:
To gain a deeper understanding of LXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.44 and its Current Ratio is at 5.44. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on March 05, 2025, Downgraded its rating to Market Perform and sets its target price to $1 from $2 previously.
On June 17, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.Leerink Partners initiated its Outperform rating on April 30, 2024, with a $5 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 15 ’24 when COATS LONNEL bought 300,000 shares for $1.60 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 247178928 and an Enterprise Value of 114147656. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.95 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 3.673 whereas that against EBITDA is -0.619.
Stock Price History:
The Beta on a monthly basis for LXRX is 1.09, which has changed by -0.6284153 over the last 52 weeks, in comparison to a change of 0.09765589 over the same period for the S&P500. Over the past 52 weeks, LXRX has reached a high of $2.45, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 35.58%, while the 200-Day Moving Average is calculated to be -39.11%.
Shares Statistics:
It appears that LXRX traded 15.32M shares on average per day over the past three months and 7047430 shares per day over the past ten days. A total of 361.49M shares are outstanding, with a floating share count of 180.38M. Insiders hold about 50.33% of the company’s shares, while institutions hold 34.65% stake in the company. Shares short for LXRX as of 1744675200 were 41331814 with a Short Ratio of 2.70, compared to 1741910400 on 39259612. Therefore, it implies a Short% of Shares Outstanding of 41331814 and a Short% of Float of 31.81.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Lexicon Pharmaceuticals Inc (LXRX) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.09 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.35 and -$0.65 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.36, with 5.0 analysts recommending between -$0.2 and -$0.53.
Revenue Estimates
Based on 5 analysts’ estimates, the company’s revenue will be $14.89M in the next fiscal year. The high estimate is $36.4M and the low estimate is $5.81M.
